Please assess the completion status of the following clinical trial:

Trial Title: A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Normal vision at distance, either natural or post corneal laser refractive surgery, with presbyopia in each eye and complaints of poor near vision that impacts activities of daily living~Exclusion Criteria:~* Use of any topical ophthalmic medications, including artificial tears other than the study medications during the study~* Corneal abnormalities in either eye that interfere with visual acuity~* History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery or any intraocular surgery~* Diagnosis of glaucoma or ocular hypertension.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Vehicle Control (Type: EXPERIMENTAL): Vehicle dosed in both eyes administered once daily during office visits 1 through 5.
- Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A (Type: EXPERIMENTAL): Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.
- Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B (Type: EXPERIMENTAL): Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.
- Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C (Type: EXPERIMENTAL): Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.
- Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C (Type: EXPERIMENTAL): Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.

Based on this trial design, predict the completion outcome and termination type (if applicable).